Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any cataract (disease) in which the cause of the disease is a mutation in the CRYAA gene.
Features include sometimes findings: Microcornea, Iris coloboma, Microphthalmia, and Progressive cataract. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 8 | Strabismus, Cataract, Nystagmus |
CRYAA encodes crystallin alpha A (173 aa). Contributes to the transparency and refractive index of the lens. Highest expression in Kidney Medulla (3.3 TPM) and Kidney Cortex (0.2 TPM).
Cataract 9 multiple types is associated with mutations in the CRYAA gene on chromosome 21.
CRYAA is classified as a druggable target with score 0.0.
Genetic testing for CRYAA is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for cataract 9 multiple types.
48 publications have been identified in PubMed for cataract 9 multiple types. Research spans Case Report / Case Series (34%), Gene Therapy / Novel Therapeutics (18%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 15 | 34% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
8 |
18% |
Research summaries | 7 | 16% |
Disease patterns and progression | 6 | 14% |
Clinical study results | 4 | 9% |
Laboratory research | 4 | 9% |
Tsivitanidou E (2026). [PMID: 41870534](https://pubmed.ncbi.nlm.nih.gov/41870534/). *Eur J Ophthalmol*. [Review / Meta-Analysis]
Kang S (2026). [PMID: 41236190](https://pubmed.ncbi.nlm.nih.gov/41236190/). *Ophthalmic Genet*. [Case Report / Case Series]
Paredes-Hernández M (2026). [PMID: 41720340](https://pubmed.ncbi.nlm.nih.gov/41720340/). *Arch Soc Esp Oftalmol (Engl Ed)*. [Case Report / Case Series]
Huang T (2026). [PMID: 41822754](https://pubmed.ncbi.nlm.nih.gov/41822754/). *Front Genet*. [Epidemiology / Natural History]
Ing A (2026). [PMID: 42091610](https://pubmed.ncbi.nlm.nih.gov/42091610/). *Ophthalmic Genet*. [Gene Therapy / Novel Therapeutics]
Chandran KR (2025). [PMID: 40125772](https://pubmed.ncbi.nlm.nih.gov/40125772/). *J Pediatr Ophthalmol Strabismus*. [Case Report / Case Series]
Berry V (2025). [PMID: 40428427](https://pubmed.ncbi.nlm.nih.gov/40428427/). *Genes (Basel)*. [Epidemiology / Natural History]
Hall J (2025). [PMID: 40138169](https://pubmed.ncbi.nlm.nih.gov/40138169/). *Ophthalmol Ther*. [Review / Meta-Analysis]
Guo D (2025). [PMID: 40449652](https://pubmed.ncbi.nlm.nih.gov/40449652/). *Prog Retin Eye Res*. [Review / Meta-Analysis]
Reis LM (2025). [PMID: 41230902](https://pubmed.ncbi.nlm.nih.gov/41230902/). *Invest Ophthalmol Vis Sci*. [Gene Therapy / Novel Therapeutics]